Objectives-We sought to investigate whether treatment with ezetimibe in combination with statins improves coronary endothelial function in target vessels in coronary artery disease patients after coronary stenting. Approach and Results-We conducted a multicenter, prospective, randomized, open-label, blinded-end point trial among 11 cardiovascular treatment centers. From 2011 to 2013, 260 coronary artery disease patients who underwent coronary stenting were randomly allocated to 2 arms (statin monotherapy, S versus ezetimibe [10 mg/d]+statin combinational therapy, E+S). We defined target vessel dysfunction as the primary composite outcome, which comprised target vessel failure during treatment and at the 6-to 8-month follow-up coronary angiography and coronary endothelial dysfunction determined via intracoronary acetylcholine testing performed in cases without target vessel failure at the follow-up coronary angiography. Coadministration of ezetimibe with statins further lowered low-density lipoprotein cholesterol levels (83±23 mg/dL in S versus 67±23 mg/dL in E+S; P<0.0001), with significant decreases in oxidized low-density lipoprotein and oxysterol levels. Among patients without target vessel failure, 46 out of 89 patients (52%) in the S arm and 34 out of 96 patients (35%) in the E+S arm were found to have coronary endothelial dysfunction (P=0.0256), and the incidence of target vessel dysfunction at follow-up was significantly decreased in the E+S arm (69/112 (62%) in S versus 47/109 (43%) in E+S; P=0.0059). A post hoc analysis of post-treatment low-density lipoprotein cholesterol-matched subgroups revealed that the incidence of both target vessel dysfunction and coronary endothelial dysfunction significantly decreased in the E+S arm, with significant reductions in oxysterol levels.
M ortality rates for patients with coronary artery disease (CAD) have decreased with advances in cardiovascular science, which includes the development of fibrinolysis and percutaneous coronary interventions, which in turn has highlighted the importance of medical treatment for secondary prevention. 1, 2 Statin is the standard agent for lipid-lowering therapy and has been proven to decrease the rates of recurrent coronary events. However, there is an unmet need for advanced pharmacotherapy beyond statin therapy to overcome the risks of residual coronary events. 3 Ezetimibe blocks the cholesterol transporter Niemann-pick C1-like 1, which is primarily expressed in the small intestine, mediates the absorption of dietary and biliary cholesterol, and effectively lowers serum low-density lipoprotein cholesterol (LDL-C) when administered alone or in combination with statins. 4 The recently published IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial) showed that the addition of ezetimibe to simvastatin therapy further decreases LDL-C levels and the rate of cardiovascular events, including myocardial infarction, in comparison to the effect of simvastatin monotherapy in patients with acute coronary syndrome. 5 In relation to cholesterol metabolism, high rates of cholesterol absorption have been found to be associated with more recurrent coronary events under statin therapy, even with equivalent LDL-C levels, in an ad hoc analysis of a Scandinavian simvastatin survival study (4S). 6 In a prospective study, the use of a high-intensity statin was found to cause greater inhibition of cholesterol synthesis and a larger enhancement of cholesterol absorption. 7 In another prospective study, a decrease in coronary events associated with statin therapy was blunted in CAD patients with high rates of cholesterol absorption. 8 These reports reveal a potential weak point in statin monotherapy: enhanced intestinal cholesterol absorption, which may counteract the LDL-C-lowering effect and increase the absorption of other atherogenic lipids, such as oxysterols. 9 Dietary oxysterols may be absorbed from the intestine and incorporated into chylomicrons and chylomicron remnants in humans, 10 a process inhibited by ezetimibe treatment. 11 We have previously shown that dietary oxysterols accelerate atherosclerotic plaque destabilization in hypercholesterolemic mice, and this acceleration is ameliorated by ezetimibe monotherapy, which is associated with decreases in serum LDL-C, oxidized LDL, and oxysterol levels. 12 These findings led us to hypothesize that ezetimibe may confer clinical benefits when used in combination with statins by acting via different mechanisms than statins.
Coronary endothelial dysfunction (CED) precedes atherogenesis and plays an important role in the progression of atherosclerosis and CAD. 1, 13 In clinical studies, CED is defined as an impairment of vasodilation in response to intracoronary acetylcholine, and it has been shown to independently predict future cardiovascular events in prospective studies. 14 Therefore, examining coronary endothelial function, which may be sensitive to lipid-lowering therapies, 15 is useful in the evaluation of cardiovascular protective effects as surrogate outcomes. 16 In clinical studies, ezetimibe monotherapy has been shown to improve endothelial function in peripheral arteries. 17 However, the effects of ezetimibe on coronary endothelial function in association with coronary events is not known.
Accordingly, we conducted a multicenter, randomized controlled trial to investigate whether treatment with ezetimibe in combination with statins improves coronary endothelial function in target coronary arteries when compared with the effect of statin monotherapy that results in equivalent target LDL-C levels (≤100 mg/dL) in patients after coronary stenting. In the CuVIC trial (Effect of Cholesterol Absorption Inhibitor Usage on Target Vessel Dysfunction after Coronary Stenting), we evaluated target vessel dysfunction (TVD), a composite of target vessel failure (TVF) 18 during the study period and CED, via intracoronary acetylcholine testing at routine follow-up coronary angiographies 6 to 8 months after index coronary stenting.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Baseline Characteristics
Patients undergoing successful percutaneous coronary intervention (n=260) were randomly allocated to receive statin monotherapy (S arm, n=131) or ezetimibe in combination with statins (E+S arm, n=129 centers and coronary stents (bare metal stent or drug-eluting stent; Figure 1 ). Patients who did not receive statin monotherapy in the S arm (n=2) were excluded from the full analysis. The baseline characteristics of the 258 patients in the full analysis set are shown in Table 1 . There were no significant differences in patient demographics, coronary risk factors, and pharmacological therapies between the 2 arms at baseline. Stented coronary arteries (right, left anterior descending, or left circumflex) were registered as the target vessels in 42 patients (33%), 66 patients (51%), and 21 patients (16%) in the S arm and in 30 patients (23%), 79 patients (61%), and 20 patients (16%) in the E+S arm, respectively. Bare metal stents were used in 129 patients, 64 in the S arm and 65 in the E+S arm, and second-generation drug-eluting stents were used in 129 patients, 65 in the S arm and 64 in the E+S arm. There were no significant differences between treatment arms in the number of stents, stent diameter, and stent length in the target vessels.
Study Treatment and Laboratory Data
The study protocol allowed for the modification of statin therapies by the participating physicians to achieve equivalent target LDL-C levels (≤100 mg/dL) in accordance with the Japan Atherosclerosis Society guidelines. 19 Prescribed statin doses were classified as higher dose, moderate dose, or lower dose based on a postmarket survey in Japan (Table I in the onlineonly Data Supplement), in which doses were set lower than those recommended in the American College of Cardiology/ American Heart Association guidelines, 20 reflecting the genetically based differences in the metabolism of statins by hepatic enzymes and in their interaction with drug transporters. 21 As a result, the use of higher-dose statins was more prevalent in the S arm than in the E+S arm ( Figure II in the online-only Data Supplement). Lipid profiles and other laboratory data at baseline and at follow-up are shown in Table 2 . The 2 treatments used in this study resulted in significant difference regarding the changes in total cholesterol, LDL-C, and apolipoprotein B (P<0.0001, ANCOVA). The levels of the cholesterol absorption markers campesterol and sitosterol significantly increased in the S arm, whereas levels of these markers decreased in the E+S arm. Lathosterol levels modestly increased in the E+S arm, in which moderate-or lower-dose statins were used (Table II and Figure II in the online-only Data Supplement). The levels of serum (malondialdehyde-modified LDL [MDA-LDL]), which represents oxidized LDL-C, were decreased by the ezetimibe treatment compared with the effect of statin monotherapy (P<0.0001, ANCOVA; Table 2 ). We identified several oxysterols, oxidized products of cholesterol, in patient sera using gas chromatography mass spectrometry (Table 3) . There were significant decreases in the levels of total oxysterols, 5β,6β-epoxycholesterol, 4β-hydroxycholesterol, 7β-hydroxycholesterol, and 27-hydroxycholesterol in the E+S arm, whereas no changes in oxysterols were observed in the S arm ( Table 3 ). The adverse drug effects reported were as follows: diarrhea or constipation in 2 patients in the E+S arm; elevated serum transaminase levels in 2 patients in the S arm and 1 in the E+S arm; and elevated creatinine kinase levels in 2 patients in the S arm and 1 in the E+S arm. None of these adverse drug effects required the discontinuation of the study treatments.
Study Flow
Study flow is shown in Figure 1 . The median duration (interquartile range) from baseline to the follow-up coronary angiography was 203 (185-236) days in the S arm and 204 (187-232) days in the E+S arm. Finally, 112 patients in the S arm and 109 in the E+S arm were included in the primary outcome analysis. The cumulative dropout rate was 14.3% in the full analysis set, and the statistical power of the analysis was maintained at >80%.
Study Outcomes: TVD and CED
Intention-to-treat analyses of the primary outcomes and end point components after 6 to 8 months of the treatments are shown in Figure 2 and in Figure 2A ). The incidence of TVF at follow-up was 23/112 (21%) in the S arm versus 13/109 (12%) in the E+S arm (P=0.0831, χ 2 test), with no target vessel-related deaths in either arm and 1 target vessel-related myocardial infarction in the S arm (Table 4 ). The cumulative ischemia-driven target vessel revascularization rates were 20% in the S arm and 12% in the E+S arm (P=0.1162, χ 2 test), and in all cases, revascularization was performed at the previously stented site. The rate of target lesion revascularization in acute coronary syndrome cases was not greater than the rate in non-acute coronary syndrome cases (16.0% versus 15.8%; P=0.97) in this study. Intracoronary acetylcholine testing among patients without TVF (89 patients in the S arm and 96 patients in the E+S arm) revealed that the incidence of CED was 52% in the S arm versus 35% in the E+S arm (P=0.0256; Figure 2B ; Table 4 ). The vasoconstrictive responses of the epicardial coronary arteries of interest are shown in Figure 2C ). The maximum vasoconstriction induced with low, middle, or high doses of acetylcholine in each subject was 49±19% in the S arm and 43±23% in the E+S arm (P=0.0295, t test; Figure 2D ), suggesting that lipid-lowering therapy with ezetimibe and statins ameliorates endothelial dysfunction in target coronary arteries.
Post-Treatment Total Oxysterol and LDL-C Levels and CED
We divided subjects into tertiles based on post-treatment total oxysterol levels and categorized the levels of LDL-C (LDL-C level: >100, n=34; 71-100, n=90; ≤70, n=90).
We additionally performed trend analysis (CochranArmitage test) on the association between oxysterol tertiles or LDL-C categories and the incidence of CED. As a result, the incidence of CED tended to be higher in the high oxysterol tertile (P=0.23, by Cochran-Armitage test) and also to be higher in the high LDL-C category (P=0.30, by Cochran-Armitage test), although the statistical analyses were underpowered. The relative risk in the oxysterol T1/high LDL-C group was 1.52 (reference: oxysterol T3/low LDL-C; Figure 3 ).
Subgroup Analysis
An analysis of the TVD risks in prespecified subgroups according to baseline characteristics is shown in Figure 4 . The benefit of the addition of ezetimibe remained significant in the following subgroups: men, and those with age ≥65 years, metabolic syndrome, hypertension, no diabetes mellitus, dyslipidemia, bare metal stent, and C-reactive protein levels <0.2 mg/dL, whereas the differences in the treatment effect in each subgroup were not statistically significant (Figure 4 ).
Post-Treatment LDL-C-Matched Subgroups
We generated subgroups by matching post-treatment LDL-C levels in the S and the E+S arms using JMP software (SAS Institute, Inc, Cary, NC) based on greedy nearest available matching in a 1:1 ratio without replacement with a caliper width of 0.05 times the SD of the logit of the LDL levels, and we performed ad hoc analyses. Among the subgroups of 62 subjects in each group with equivalent LDL-C levels (74±3 versus 74±3 mg/dL; P=0.99, Student t test), the incidence of TVD at follow-up was significantly lower in the E+S arm (36/62 (58%) in the S arm versus 23/62 (37%) in the E+S arm; P=0.019, χ 2 test; Figure 5A ), and the incidence of CED among patients without TVF (50 patients in the S arm and 54 in the E+S arm) was 48% in the S arm versus 28% in the E+S arm (P=0.033, χ 2 test; Figure 5B ). Although total cholesterol, triglyceride, high-density lipoprotein cholesterol, apolipoprotein A1, apolipoprotein B, high-sensitivity C-reactive protein, and MDA-LDL levels were similar among the LDL-C-matched subgroups, total oxysterol levels, which did not change in response to statin monotherapy, were significantly decreased by the coadministration of statins with ezetimibe, that is, from 1772±1125 to 1626±114 ng/mL in the S arm (−8%; P=0.90, paired t test) versus from 1854±1359 to 1453±114 ng/mL in the E+S arm (−22%, P=0.019, paired t test; P=0.0108, ANCOVA; Table III in the online-only Data Supplement). 
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Discussion
The primary findings of the CuVIC trial were that a lipid-lowering therapy with ezetimibe in combination with statins had the following results when compared with the effects of statin monotherapy: (1) LDL-C levels were lowered, even added to lower doses of statins; (2) there was a decrease in TVD, which comprised target vessel-related death, nonfatal myocardial infarction, ischemia-driven repeat revascularization, and CED among CAD patients after coronary stenting; and (3) the levels of atherogenic lipids, including oxysterols and oxidized LDL, were decreased. To the best of our knowledge, the CuVIC trial investigates the effect of ezetimibe in combination with statins on coronary endothelial function among CAD patients after coronary stenting. The decrease in TVD indicates the beneficial effects of ezetimibe in combination with statins, which may lead to a decrease in future cardiovascular events. This conclusion is supported by the findings of the IMPROVE-IT study, 5 which has shown the effectiveness of the combination of simvastatin and ezetimibe over simvastatin alone in reducing the occurrence of cardiovascular events, including myocardial infarction. Meta-analyses of cholesterol treatment trials have demonstrated that decreases in the risk of cardiovascular events are proportional to decreases in LDL-C, 5, 22 supporting the lower is better concept or the LDL principle of lipid-lowering therapy. 5 Importantly, the LDL-Cmatched subgroup analysis in this study indicates that ezetimibe may possess beneficial effects beyond LDL-C levels by lowering oxysterols to ameliorates endothelial dysfunction.
Coronary Endothelial Dysfunction
Endothelial dysfunction precedes atherogenesis and plays an important role in the progression of atherosclerosis. 1, 13 Several studies have demonstrated that CAD patients with endothelial dysfunction are at greater risk for cardiovascular events than patients with normal endothelial function. 16 In addition to its prognostic values, assessing coronary endothelial function is also useful because it responds to lipid-lowering statin therapy in a short period (6-8 months). 15 Therefore, coronary endothelial function is valuable in evaluating cardiovascular protective effects as a surrogate outcome. However, one of the disadvantages of intracoronary acetylcholine testing to evaluate coronary endothelial function is its invasiveness, especially in coronary arteries with significant stenotic lesions. Previously, peripheral endothelial dysfunction and CED, the development of stent restenosis after percutaneous coronary intervention, 23, 24 and other cardiovascular events have been found to be independently and closely related. Considering the role of CED as a predictor of TVF, in this trial, we constructed a definition of Figure 3 . Total oxysterol and low-density lipoprotein cholesterol (LDL-C) levels and coronary endothelial dysfunction. Subjects were divided into tertiles of total oxysterols, and LDL-C levels were categorized (LDL-C >100, n=34; 71-100, n=90; and ≤70, n=90). The incidence of coronary endothelial dysfunction tended to be higher for the high oxysterol tertile (T1; P=0.21, CochranArmitage test) and high LDL-C level (P=0.36, Cochran-Armitage test). The relative risk in the T1/high LDL-C group was 1.52 (reference: oxysterol T3/low LDL-C). . The use of this definition of TVD decreased the number of subjects excluded from the analysis and effectively maintained the statistical power of our analysis at >80%. As a result of this trial, we were able to show the effectiveness of ezetimibe when coadministered with statins, which was primarily achieved by ameliorating CED (Table 4) , in a relatively small number of patients after coronary stenting.
Cholesterol Absorption and Lipid Oxidation
Statins have direct effects on vascular endothelium that enhance the NO pathway [25] [26] [27] in addition to lipid-lowering effects; however, the clinical importance of this pleiotropic effect of statins is not yet firmly established. Endothelial dysfunction in hypercholesterolemia is attributed primarily to oxidized LDL, which has been shown to decrease NO bioavailability in endothelial cells through the inhibition of the expression of NO synthase 28 and the production of reactive oxygen species via the lectin-like oxidized LDL receptor (LOX-1). 29 Among several indicators of oxidized LDL, MDA-LDL represents malondialdehyde-induced modifications of apolipoprotein B 30 and is associated with endothelial dysfunction. 31 Therefore, lipid-lowering therapies per se improve endothelial function at least in part through decreasing the levels of oxidized LDL. 29, 32 Ezetimibe inhibits cholesterol absorption; in contrast, statin monotherapy enhances it (Table II in the online-only Data Supplement). Although markers of high rates of cholesterol absorption are associated with a high risk of cardiovascularrelated mortality among patients with similar LDL-C levels, 8, 33 the mechanisms responsible for this association are not fully understood. Recently, the PRECISE-IVUS study (Plaque Regression With Cholesterol Absorption Inhibitor or Synthesis Inhibitor Evaluated by Intravascular Ultrasound) 34 demonstrated the additional effects of ezetimibe on reducing coronary plaque volume when coadministered with statin, especially in acute coronary syndrome patients, and noted the effect of ezetimibe beyond lowering LDL-C with changes in the levels of markers of cholesterol absorption.
In this study, ezetimibe administered with statins significantly decreased oxysterol levels, along with LDL-C and MDA-LDL levels, in the E+S arm. In addition, among the subgroups with equivalent LDL-C levels, total oxysterol levels were still significantly decreased in the E+S arm (Table III in the onlineonly Data Supplement). Higher post-treatment oxysterol levels and higher post-treatment LDL-C levels were associated with a higher incidence of CED (Figure 3) , supporting the notion that high oxysterols and high LDL-C might cause endothelial dysfunction. Several oxysterols have been identified in humans and atherosclerotic animal models. 9, 12 Although there are several nonhuman studies suggesting a detrimental role of 7-KC 35 and 27-hydroxycholesterol 36, 37 on endothelial function, this study shows the association of oxysterols with endothelial dysfunction in humans. Treatment with ezetimibe was associated with the inhibition of sterol absorption and decreases of both enzymatic (intrinsic) and nonenzymatic oxysterols through the inhibition of sterol absorption. We performed a factor analysis and found that the changes in campesterol, LDL-C, MDA-LDL, and 27-hydroxycholesterol levels during the treatment period of this study formed a cluster ( Figure IIIA and Table  IV in the online-only Data Supplement), which was confirmed by the correlations of each pair (Figure IIIB and Table V in the online-only Data Supplement). These exploratory findings support the notion that ezetimibe, a cholesterol absorption inhibitor, may possess beneficial effects for maintaining coronary endothelial function through oxysterol lowering, which may decrease future cardiovascular events beyond the LDL-C-lowering effect of statin monotherapy.
Limitations
Several limitations should be noted in this study. First, we defined TVD as a primary outcome of the CuVIC trial, mainly based on the changes in coronary endothelial function, to investigate the effect of ezetimibe when combined with statin treatment. Although coronary endothelial function is an established surrogate outcome to predict future coronary events, 16 it remains to be elucidated whether the modest improvement of coronary endothelial function in target vessels may secure the reduction of future coronary events. At the time of writing, the large-scale IMPROVE-IT trial 5 has just provided concrete evidence of the beneficial effect of ezetimibe in suppressing coronary events, such as myocardial infarction. Second, the cumulative target vessel revascularization rates were relatively high in this trial (20% in the S arm and 12% in the E+S arm). Participating physicians performed revascularizations based on the presence of angiographic restenosis and functional ischemia (both definitions are described in Materials and Methods in the online-only Data Supplement), which was confirmed by a blinded independent end point committee through a quantitative coronary angiogram analysis and a review of medical records. The frequent use of bare metal stents (50% in each arm) and the routine performance of tests for functional ischemia before and at the follow-up coronary angiography might have raised the incidence of target vessel revascularization. Third, the study protocol allowed for the modification of the statins by the participating physicians to achieve equivalent target LDL-C levels (≤100 
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mg/dL) in accordance with the Japan Atherosclerosis Society guideline, 19 and the levels of statins administered were lower than that used in previous clinical trials involving non-Asian patients. Statin doses approved by the Japan Pharmaceuticals and Medical Devices Agency and statin doses recommended in the Japanese guidelines are set lower because of a heightened response to statins in Asians, which is related to genetically based differences in the metabolism of statins. 21 The use of statins at lower doses might heighten the impact of oxysterol lowering as a potential pleiotropic effect of ezetimibe, in agreement with the subgroup analysis (Figure 3) showing that the impact of oxysterol levels was larger in high LDL-C category.
Conclusions
The CuVIC trial has shown that ezetimibe administered with statins improves functional prognoses compared with the effects of statin monotherapy, ameliorating endothelial dysfunction in stented coronary arteries, and this effect was associated with larger decreases in the levels of atherogenic oxysterols.
